NewAmsterdam (NAMS) Q2 Revenue Jumps 49%
NewAmsterdam Pharma (NASDAQ:NAMS), a clinical-stage biopharmaceutical company focused on developing oral therapies for cardiometabolic diseases, delivered its Q2 2025 earnings report on August 6, 2025. The most important news from the release was GAAP revenue of $19.1 million, a significant outperformance against the $12.8 million consensus estimate, mainly driven by milestone payments tied to its Menarini partnership in Europe. Net loss (GAAP) sharply improved year over year, narrowing as research and development spending declined, even as selling, general, and administrative costs climbed with commercial preparations. Overall, the quarter showed progress across clinical milestones, reinforced by a robust cash position and advancement toward pivotal regulatory events, while costs continued to rise as the company gears up for potential product launch.
Source: Analyst estimates for the quarter provided by FactSet.
NewAmsterdam Pharma develops oral therapies for cardiometabolic diseases. Its lead product candidate is obicetrapib, a daily oral cholesteryl ester transfer protein (CETP) inhibitor for lowering LDL-C (so-called “bad” cholesterol). The company operates in the pre-commercial stage, with revenues to date coming from research partnerships rather than drug sales.
Source Fool.com
